Men With Advanced Prostate Cancer, Be Informed About Your Genetics!

Video
Conference|ASCO Annual Meeting: Genitourinary

In this video, Dr. Heather Cheng briefly outlines the GENTleMEN study on the impact of genetic testing for men with advanced prostate cancer. 

In this video, Dr. Heather Cheng briefly outlines the GENTleMEN study of the impact of genetic testing for men with advanced prostate cancer.

 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content
Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Kyle Doherty
September 9th 2025
Article
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
September 9th 2025
Podcast
The safety and tolerability of nivolumab/chemotherapy in non–small cell lung cancer were manageable and consistent with its profiles in other clinical scenarios.

Adjuvant Nivolumab/Chemo Reduces Recurrence Risk in Resected NSCLC

Roman Fabbricatore
September 9th 2025
Article
Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
September 9th 2025
Podcast
Ivonescimab plus chemotherapy following progression after a third-generation TKI showed consistent efficacy across EGFR-mutated NSCLC subgroups.

Ivonescimab/Chemo After TKI Progression Improves PFS in EGFR-Mutated NSCLC

Ashley Chan
September 9th 2025
Article
The trial’s primary end points were EFS and OS. Secondary end points included mPR rate, pCR rate, AEs, and quality of life.

Perioperative Pembrolizumab Combo Improves Responses in NSCLC Subgroups

Russ Conroy
September 9th 2025
Article